The news adds two concrete pillars to the Keytruda “patent wall”: (1) Phase 3 OptiTROP-Lung05 shows Keytruda + sac-TMT beats ...

Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...

Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...

Merck reported first-quarter results that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products. The pharmaceutical giant also narrowed its 2026 sales ...

Merck received a positive opinion from the European Medicines Agency backing approval of its Keytruda-Padcev combination for a subset of bladder patients.

Shares of Merck MRK rose nearly 6% on Friday after the company announced that the EMA’s Committee for Medicinal Products for ...

This synergistic rationale drove the two-part structure of Toragen’s Phase 1 trial, with monotherapy in Part 1 and ...

Merck reported higher first-quarter sales and raised its full-year earnings guidance as demand for its flagship Keytruda cancer drug continues to grow. Sales rose 5% to $16.29 billion, boosted by 12% ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive ...

Merck narrows 2026 outlook, but analysts see revision as less compelling Investors focus on pipeline and efforts to reduce reliance on Keytruda Merck booked $3.62-per-share charge for Cidara buyout ...

Merck (MRK) reported Q1 2026 revenue of $16.29B, up 4.87% year-over-year and beating consensus estimates, with KEYTRUDA sales jumping 12% to $8.03B and WINREVAIR surging 88% to $525M despite a $9.0B ...

The late-stage miss shakes analyst confidence in Regeneron’s clinical execution, according to BMO Capital Markets, also ...